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Abstract
BACKGROUND
The current epidemiology of inflammatory bowel disease (IBD) in the multi-
ethnic United Kingdom is unknown. The last incidence study in the United
Kingdom was carried out over 20 years ago.
AIM
To describe the incidence and phenotype of IBD and distribution within ethnic
groups.
METHODS
Adult patients (> 16 years) with newly diagnosed IBD (fulfilling Copenhagen
diagnostic criteria) were prospectively recruited over one year in 5 urban
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catchment areas with high South Asian population. Patient demographics, ethnic
codes, disease phenotype (Montreal classification), disease activity and treatment
within 3 months of diagnosis were recorded onto the Epicom database.
RESULTS
Across a population of 2271406 adults, 339 adult patients were diagnosed with
IBD over one year: 218 with ulcerative colitis (UC, 64.3%), 115 with Crohn's
disease (CD, 33.9%) and 6 with IBD unclassified (1.8%). The crude incidence of
IBD, UC and CD was 17.0/100000, 11.3/100000 and 5.3/100000 respectively. The
age adjusted incidence of IBD and UC were significantly higher in the Indian
group (25.2/100000 and 20.5/100000) compared to White European (14.9/100000,
P = 0.009 and 8.2/100000, P < 0.001) and Pakistani groups (14.9/100000, P = 0.001
and 11.2/100000, P = 0.007). The Indian group were significantly more likely to
have extensive disease than White Europeans (52.7% vs 41.7%, P = 0.031). There
was no significant difference in time to diagnosis, disease activity and treatment.
CONCLUSION
This is the only prospective study to report the incidence of IBD in an ethnically
diverse United Kingdom population. The Indian ethnic group showed the
highest age-adjusted incidence of UC (20.5/100000). Further studies on dietary,
microbial and metabolic factors that might explain these findings in UC are
underway.
Key words: Inflammatory bowel disease; Ethnicity; Epidemiology; Incidence; Phenotype
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: We performed a United Kingdom multicentre prospective cohort study to
describe the incidence of inflammatory bowel disease and differences within ethnic
groups. Seven urban centres with high ethnic background population recruited 339 cases
over a 1 year period. Patients of Indian ethnicity were almost three times more likely to
have UC than White Europeans. The impact of diet and environmental factors on this
high risk population requires further study.
Citation: Misra R, Limdi J, Cooney R, Sakuma S, Brookes M, Fogden E, Pattni S, Sharma N,
Iqbal T, Munkholm P, Burisch J, Arebi N. Ethnic differences in inflammatory bowel disease:
Results from the United Kingdom inception cohort epidemiology study. World J
Gastroenterol 2019; 25(40): 6145-6157
URL: https://www.wjgnet.com/1007-9327/full/v25/i40/6145.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i40.6145
INTRODUCTION
The incidence of inflammatory bowel disease (IBD) is highest in industrialised regions
of North America and Europe[1]. Incidence rates in Europe and North America are
stable  unlike  less  industrialised  countries  where  they  are  increasing.  Recent
epidemiologic studies report rates of IBD incidence rates of 15.2/100000, 24.5/100000
and 0.5-3.4/100000 for Europe, Australia and South East Asia respectively[2,3]. The last
incidence study in the United Kingdom comes from a population of 135723, which
reported an incidence of 13.9/100000 for ulcerative colitis (UC) and 8.3/100000 for
Crohn’s disease (CD) in a predominantly White European population (98%)[4]. Some
regions  in  the  United  Kingdom  have  a  large  and  increasing  South  Asian  (SA)
population extending back to a migrant flow in the 1950s[5].  Early studies of this
migrant population suggested a higher UC incidence than European populations
(10.8/100000 vs 5.3/100000) with an increase over time between 1980 and 1990[6-8].
However, the disease phenotype in the SA population was not homogenous. For
instance the Bangladeshi population were less likely than White Europeans to have
UC and presented with aggressive CD[9,10]. Differences in incidence and phenotype
have also been reported for African-Americans, Hispanics and East Asians in the
United States[11-14]. The reasons for these differences are unclear. An environmental
trigger on genetically susceptible individuals is likely, given that migrants tend to
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adopt the disease incidence of their adopted country rather than country of origin[15].
Further  studies  on  migrant  populations  may  offer  new  insights  into  disease
pathogenesis[16]. The prevailing reference point for the epidemiology of IBD in the
United Kingdom is drawn from retrospective, single centre studies carried out almost
two decades ago[17].  We aimed to describe incidence and phenotype of IBD in the
United Kingdom across ethnic groups as an update on the previous literature and to
justify future explanatory studies.
MATERIALS AND METHODS
Study populations
The study populations were determined by examining the latest United Kingdom
census data from 2011[5]. All United Kingdom residents are legally bound to complete
the national survey sent out every 10 years. Over 94% of the population completed the
census survey in 2011, which required respondents to select their ethnic group from a
list  of  standardised  categories  set  up  and  defined  by  the  National  Statistics
Harmonisation  group [ 1 8 ] .  These  are  White,  Mixed  ethnic  group,  Asian,
Black/African/Caribbean and Other ethnic groups. The Asian category is subdivided
into Indian, Pakistani, Bangladeshi, Chinese and Asian Other. White and two SA
groups (Indian and Pakistani, 44.3% of ethnic groups) offered the largest population
sizes and comparisons between these three were undertaken.
High ethnically diverse populations were identified by examining the census data
and selecting regions where more than 10% of the background population was non-
White European. The census areas are divided into local authorities. The selection of
recruiting hospitals was based on matching the hospital catchment area to the local
authority area. For example, Birmingham is the largest single local authority area in
England with a population of over one million. Therefore, three hospitals serving
central Birmingham were recruited to cover the relevant area. Seven centres covering
a population of 2271406 with a SA population of 443303 participated: Northwest of
England (Pennine NHS Trust,  Northeast Manchester),  East Midlands (University
Hospitals of Leicester), four in the West Midlands (University Hospital Birmingham,
Heart  of  England  NHS  Trust,  South  West  Birmingham  NHS  Trust  and  Royal
Wolverhampton NHS Trust)  and North West London (London North West NHS
Trust. Each centre has its own defined catchment area and the investigators at each
centre formed the United Kingdom Inception Epidemiology study group. To ensure
patients came from the background population, patients living outside the designated
uptake area at the time of diagnosis were excluded.
Recruitment
All new diagnoses of adult IBD aged 16 years over a one-year period commencing
February 1st,  2016 and living in the predefined catchment areas by postcode were
prospectively included. Cases were required to meet the Copenhagen Diagnostic
Criteria for CD and UC to conform with the case definitions used in the previously
validated Epi-IBD study[19,20].
Copenhagen diagnostic criteria for Crohn’s disease
Copenhagen diagnostic criteria for CD (at least two of the criteria present): (1) History
of abdominal pain, weight loss and/or diarrhoea for more than three months; (2)
Characteristic  endoscopic  findings  of  ulceration  (aphthous  lesions,  snail  track
ulceration) or cobble stoning or radiological features of stricture or cobble stoning; (3)
Histopathology consistent with CD (epithelioid granuloma of Langerhans type or
transmural discontinuous focal or patchy inflammation); (4) Fistula and/or abscess in
relation to affected bowel segments.
Copenhagen diagnostic criteria for ulcerative colitis
Copenhagen diagnostic criteria for UC (all three of the criteria present): (1) History of
diarrhoea  and/or  rectal  bleeding  and  pus  for  more  than  one  week  or  repeated
episodes;  (2)  Characteristic  endoscopic  findings  of  continuous  ulceration,
vulnerability  or  granulated  mucosa;  (3)  Histopathology  consistent  with  UC
(neutrophils within epithelial structures, cryptitis, crypt distortion, crypt abscesses).
Cases with endoscopic and histologic evidence of chronic IBD without fulfilment of
diagnostic criteria for UC and CD but in need of treatment were classified as IBD
unclassified (IBDU). Each case was then examined by the author (RM) to ensure the
diagnostic criteria were fulfilled.
Case definition
In the United Kingdom, IBD patients are diagnosed and managed in secondary care
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by a dedicated gastroenterology team. Incident IBD cases were identified through
three pathways: (1) New referrals from primary care with signs and symptoms of IBD;
(2) New IBD patients referred by the attending internal physician or surgeon at the
time  of  hospitalisation;  and  (3)  Patients  referred  from  endoscopy  with  IBD.
Endoscopy, histology and radiology reports were searched on a weekly basis for key
words: UC, colitis, CD and proctitis to enhance case capture. Participating centres
were asked to screen endoscopy, radiology and histology reports on a weekly basis to
identify incident cases.  Centres were given expected incidence targets calculated
based on  the  background population.  Each  centre  was  required  to  submit  their
recruitment figures monthly. Centres falling behind the expected recruitment target
were quickly identified. The recruitment methodology was checked and advice given
to ensure all  methods of  a  case capture were being utilised.  Cases  could still  be
entered on the database if discovered after the recruitment period up to 6 months
after the end of recruitment; this gave additional time for cases which were initially
missed and subsequently identified to be included in the study. Case report forms
were  provided  to  the  centres  for  data  collection.  IBD  phenotype  was  classified
according to Montreal classification[21].  All treatments commenced within the first
three months after diagnosis either single or in combination were defined as reported.
A surgical intervention was defined as a surgical procedure related to IBD within
three months of diagnosis.
Data collection
Data were collected using standardised case report forms at the first patient visit
within three months of diagnosis and entered onto the validated Epicom database[22].
The database was modified to include ethnicity reporting, country of birth and time
living  in  country.  The  data  entry  schemes  included  diagnostic  criteria  scheme
comprising data on diagnosis, disease extent, behaviour and patient demographic
details. Smoking status and family history of IBD were also recorded. Disease activity
at diagnosis was recorded by the physician using Harvey–Bradshaw index (HBI) for
CD and Simple Clinical Colitis Activity Index (SCCAI) for UC [23,24].  Patients were
provided  with  an  environmental  questionnaire  designed  by  the  International
Organisation of IBD. Participants were asked to complete their responses and return
the questionnaire to their local centre.
Data validity
A monthly  remote  monitoring exercise  was  performed to  verify  captured cases.
Random  selection  of  a  patient  number  was  followed  by  request  for  relevant
participating site  to  send anonymised copies  of  endoscopy,  histology and clinic
reports.  These  were  cross  checked  with  the  corresponding  information  on  the
database by the authors (RM and SS). Written feedback was given to centres to correct
any errors identified. Missing data were highlighted and relevant centres informed.
Data input was monitored in real time.
Ethical considerations
The study was approved by the London Northwest NHS Trust and National Research
Ethics  Service  (REC number14/EM/1290).  Study recruitment  was supported by
National Institute of Health Research Clinical Research Network United Kingdom
with dedicated research nurses at each centre.
Biostatistics statement
The statistical  review of the study was by a statistican, Paul Bassett  of St.  Marks
Hospital and Academic Institute.
Statistical analysis
Crude incidence rates were calculated for IBD, CD, and UC based on the number of
patients diagnosed compared with the total population at risk. Incidence rates were
age standardised using the European age standardised rate and reported with 95%
confidence intervals (CI), assuming a Poisson distribution[25]. Data from the Indian and
Pakistani  cohorts  were  compared  with  the  White  European  cohort  using  the
Mann–Whitney U-test for continuous variables such as age at diagnosis, and the chi-
squared test for categorical variables. P values < 0.05 were considered statistically
significant.
RESULTS
Study population
Across a population of 2271406 adults from five regions, 339 patients were diagnosed
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with IBD over the year study period: 192 (56.6%) were male. In total 218 patients were
diagnosed with UC (64.3%),  115 with CD (33.9%) and 6 with IBDU (1.76%).  The
absolute population sizes of the White European, Indian, Pakistani and Other ethnic
groups were 1387047, 239814, 152264 and 492461 respectively.
Incidence and phenotype of IBD
The crude incidence of IBD, UC and CD for the total population was 17.0/100000,
11.3/100,000  and  5.3/100000  respectively.  The  distribution  of  UC  in  the  total
population was 23.7% proctitis (n = 51), 34.4% left sided disease (n = 74) and 41.9%
with extensive involvement (n = 90). The overall CD disease location showed ileal
involvement in 34.4% (n = 40), colonic disease 31.2% (n = 36) and ileo-colonic disease
in  31.0%  (n  =  35).  Disease  behaviour  was  inflammatory  in  75.9%  (n  =  88)  and
stricturing 16.4% (n = 19). Perianal involvement was noted in 7.8% (n = 14) of cases at
diagnosis.
Comparison of demographic data between ethnic groups
The demography of the main three populations is shown in Table 1. Ethnicity data
was missing for 5/339 cases. The median age at diagnosis for CD was lowest in the
Other ethnic groups (19 years) and highest in the White European group, however
there were no statistical differences between the groups. There was a greater male
predisposition to IBD in Indian (61.8%) and Pakistani (66.7%) groups compared with
White Europeans (50.2%) although not significant.  Indians,  Pakistanis  and other
ethnic groups with UC were significantly more likely to be non-smokers than White
Europeans (P = 0.0001, P = 0.01, P = 0.0001 respectively). The majority of patients of
Indian ethnicity (85.2%) were born in the United Kingdom. There was no significant
difference in family history of IBD between ethnic groups (5.7% Whites, 6.6% Indians
and 11.1% Pakistanis).
Comparison of incidence between ethnic groups
The crude and age adjusted incidence rates are shown in Figure 1 and Table S1. The
age adjusted incidence of IBD and UC was higher in the Indian group (25.2/100000
and 20.5/100000) compared with White European and Pakistani groups. Most Indian
UC cases (45/55: 81.8%) were diagnosed in Leicester and North West London.
Comparison of incidence across adult age spectrum between ethnic groups
The variation in incidence rate by age is shown in Figure 2. There is a consistently
higher incidence of UC in the Indian group between 15-40 years compared to the
other groups. In comparison the pattern of CD incidence was similar across ethnic
groups (Figure S1).
Ulcerative colitis
Disease location was similar between White Europeans and Indians for proctitis
(21.7% vs 21.8%) and left sided (36.5% vs 25.4) however Indians were significantly
more likely to have extensive disease (41.7% vs 52.7%, P = 0.03) (Figure 3). Left sided
disease was the predominant disease extent in Pakistani and other ethnic groups
(41.2% and 39.2%).
Crohn’s disease
Ileal disease was the predominant phenotype in the White European group (38.8%)
whereas colonic disease was most common in the Indian group (46.2%) (Figure 4).
There was no significant difference in disease location. There were insufficient cases
in  the  other  ethnic  groups  for  meaningful  comparison.  Inflammatory  disease
behaviour (B1) was the most common presentation in all  ethnic groups. Perianal
disease  was  more  common  in  Indians  (23.1%)  compared  with  Whites  (11.4%)
although these differences were not significant.
Disease activity
The mean SCCAI and HBI scores at diagnosis are shown in  Table S2 . Compared to
the White European group, mean SCCAI scores were highest in the Indian group (6.3
vs 5.1). The Pakistani group had the highest HBI scores (6.8 vs 6.2). There were no
significant differences in disease activity indexes at presentation between groups.
Initial treatment
Treatment data was available for  183/218 UC patients  and 105/115 CD patients
(Table 2). 5-aminosalicylic acid treatment was the most common initial treatment for
UC in  White  European and Indian  patients  (81.5% and 89.4%).  Steroid  use  was
comparable  between  the  two groups.  (33.3% and 34.0%).  Nine  White  European
patients (8.3%) required rescue therapy at diagnosis with ciclosporin or infliximab. No
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Table 1  Demographics of incident inflammatory bowel disease patients categorised by ethnicity
White European (n = 205) Indian(n = 68) Pakistani (n = 24) Other (n = 37)
Male sex, n (%) 109 (53.2) 42 (61.8) 16 (66.7) 25 (83.3)
Median age, yr (IQR range)
CD 35 (25-54) 32 (29-35) 29 (23-44) 19 (16-27)
UC 40 (28-59) 38 (29-50) 29 (23-37) 34 (25-45)
Median time from symptom onset to diagnosis, mo (IQR)
CD 2.9 (0.9-8.5) 3.0 (2.0-6.0) 3.5 (2.0-5.3) 3 (2.0-3.2)
UC 2.3 (1.0-6.0) 2.5 (0.98-4.0) 2.7 (2.0-6.2) 2.5 (1.7-3.4)
Smoking history, n (%)
CD
Never 15 (22.0) 3 (33.3) 2 (40) 3 (60)
Ex-smoker 35 (51.4) 3 (33.3) 1 (20) 1 (20)
Current 18 (26.4) 3 (33.3) 2 (40) 1 (20)
UC
Never 35c (38.0) 28a (75.7) 7b (77.8) 17a (85.0)
Ex-smoker 35 (38.0) 7 (19.0) 1 (11.1) 2 (10.5)
Current 22 (24.0) 2 (5.4) 1 (11.1) 1 (5.3)
Born in the United Kingdom (%) 91.2 85.2 66.6 89.9
Family history of IBD, n (%) 9 (5.7) 4 (6.6) 2 (11.1) 1 (3.3)
Significant difference in non-smoking (aP < 0.001) between Indian and White European; Significant difference in non-smoking (aP < 0.01) between Pakistani
and White European; Significant difference in non-smoking
(cP < 0.001) between Other and White European. CD: Crohn’s disease; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; IQR: Interquartile range.
patients  from the  other  groups  required  rescue  therapy.  Two White  Europeans
patients (1.9%) underwent surgery during their index presentation. 5-aminosalicylic
acids, steroid and immunomodulator treatment were the most common therapies
used at diagnosis for White Europeans with CD. Biologic therapy was utilised in
14.6%  of  cases  and  surgery  required  at  index  presentation  in  3.7%.  The  small
population  of  Indians  and  Pakistanis  with  CD  make  it  difficult  to  make  valid
comparisons of the data.
DISCUSSION
This is the first prospective IBD inception cohort study in England. The incidence of
UC in the overall population was higher than CD and comparable to the most recent
data from Western Europe (IBD 18.5/100000,  UC 9.8/100000 CD 6.3/100000 and
IBDU 2.4/100000)[2]. We observed differential incidence rates between ethnic groups
whereby Indians  showed a  UC incidence rate  of  20.5/100000 double  that  of  the
Pakistani group (11.2/100000) and almost three times the White European population
(7.5/100000).
The high incidence of UC in SA is well recognised, however the incidence observed
in our Indian sub-group is the highest reported. This could be because many of the
previous studies looked at the SA group collectively rather than sub-groups, despite
recognised cultural and lifestyle difference between people of Indian, Pakistani and
Bangladeshi origin. In Leicester, where 76.2% of the SA population is of Indian origin,
the UC incidence rate for SAs in the 1980s was 10.3/100000 compared to our results
for Indians living in Leicester where the incidence was 31/100000[5,6]. These are the
only results that can be compared to show a change in incidence of IBD in the SA
population in England.
Canada also  hosts  a  large SA population.  In  the  province of  Ontario,  SAs are
predominantly Indian origin, however, in contrast to our findings they showed a
lower UC incidence rate compared with non-immigrants (5/100000 vs 11.3/10000)[15].
However, it should be noted that the SA community studied was predominantly first
generation  immigrants  unlike  our  cohort  where  78%  were  born  in  the  United
Kingdom. More akin to our population is the study from British Columbia, where UC
incidence rate reported for second generation SAs born in Canada was higher than for
non-SAs (6.7/100000 and 0.96/100000)[26]. These findings suggest that environmental
factors  related  to  the  country  of  birth  might  influence  the  onset  of  UC  in  SA
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Figure 1
Figure 1  Ethnic differences in age-adjusted incidence rates with standard error bars for inflammatory bowel disease in England. IBD: Inflammatory bowel
disease; CD: Crohn’s disease; UC: Ulcerative colitis; IBDU: Inflammatory bowel disease unclassified.
populations.
Analysis of comparative incidence rates according to country of birth for our Indian
population, would have been useful to support the hypothesis were it not for the
small proportion born outside the United Kingdom introducing risk of bias. Lower
incidence  rates  for  Indians  living  in  India  would  also  support  the  role  of
environmental factors. However, there is very little,  and archaic data from India.
Using house to house questionnaires to record symptoms of UC, a study in 2003
reported an incidence rate of 6.02/100000[27] for a background population of 51910,
much smaller that our Indian subgroup population of 239614 people.
The reasons for the higher incidence of UC compared with other groups living in
the same environment as well as Indians living in India, remain speculative at this
stage. Early-life exposure to western environmental triggers for a cohort with genetic
susceptibility  to  IBD is  plausible,  particularly  as  North  Indians  harbour  unique
susceptibility  genes  for  UC  and  the  United  Kingdom  Indian  population  is
predominantly  of  North  Indian  origin[6,28-30].  These  susceptibility  genes  may  be
switched on by the ‘Western’ environment in the form of change in diet, different
microbial exposure or environmental pollutants with genes that incur heightened
susceptibility  over  those  living  in  the  West.  This  theory  is  supported  by  the
observation of a younger age of onset in the Indian population demonstrated in the
incidence by age group analysis.
Dietary habits differ between the SA sub-groups and might explain some of the
observed differences. A recent study of IBD patients in India suggested vegetarianism
maybe protective in this cohort[31]. As vegetarianism is higher in Gujarati populations
(North Indians), who form the predominant ethnic group in North West London and
Leicester, we would have expected a lower not higher UC incidence rates for these
regions[32,33]. The unexpected incidence is likely to be due to the change to a western
diet. Hindu UC patients living in Leicester reported a significant deviation from their
traditional diet[34]. Dietary patterns in turn affect the gut microbiome[35]. Consumption
of a Western diet was associated with a pro-inflammatory microbial profile with
increases in Escherichia coli and reduced protective bacteria in mouse models[36]. The
microbiome is also affected by smoking which protects against UC[37]. Seventy-two
percent of the Indians in our study had never smoked compared with 36% of White
European. Loss of this protective effect may have predisposed this sub-group to UC.
Extensive disease phenotype was significantly more common in the Indian group,
findings which are consistent with reports from other studies[8,38-40].
Our study has several strengths. The United Kingdom National Health Service
(NHS) offers standard referral pathway from primary to secondary care across the
country with access to free healthcare readily available at diagnosis and for long-term
care minimising the risk of missing patients from lack of access to healthcare. We used
standardised  methods  for  pre-defined  case  ascertainment  and  reviewed  this
throughout the study. Furthermore, the prospective study design and real time data
auditing reduced the probability of missing data and avoided coding errors inherent
to retrospective studies.
We also recognise the limitations. We may have missed patients diagnosed in the
private sector however the number are expected to be small given the low incidence
of IBD and small % of population covered by private healthcare[41,42]. Moreover, most
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Figure 2
Figure 2  Ulcerative colitis incidence by ethnicity over adult age spectrum.
patients transfer their care to the NHS since health insurance cover precludes long-
term  care.  Missed  cases  are  unlikely  to  impact  our  conclusions  of  a  higher  UC
incidence rate instead they would be expected to increase the incidence rate further
rather than reducing it. Nevertheless, we tried to capture these patients to include all
diagnosis over one year even if referred to hospital after the year recruitment. We
may have  also  missed patients  who sought  medical  attention  and diagnosed in
hospitals  outside  their  catchment  area;  this  would  underestimate  rather  than
overestimate our reported incidence. From an audit of newly diagnosed IBD cases
across North West London, only three new UC cases living in the catchment area of
London North West NHS trust were identified at other sites over the recruitment
period. Another limitation is the un-adjusted analyses for confounding variables, such
as  occupation,  education  and  socioeconomic  status.  Lastly,  the  epidemiology
description for the ethnic population depended on standardised categories used in
national  census  data  rather  than  the  sub-population  genetic  predisposition.
Heterogeneity  within  the  Indian  population  is  well  described  with  genetic  and
linguistic categories attributed to different ancestral origins as well as the remapping
of boundaries between India, Pakistan and Bangladesh[43,44].  Although we did not
analyse  genetic  predisposition in  our  study,  most  of  the  population in  the  high
incidence regions are of Gujarati speaking and of North Indian origin[32,33].
In conclusion, this is the first prospective study reporting the incidence of IBD in
five ethnically diverse populations in the England.  SAs of  Indian origin had the
highest age-adjusted incidence rates for UC compared with other Asians (Pakistanis)
and White Europeans in the United Kingdom. The majority of SAs were born in the
United Kingdom suggesting that the complex interactions with the exposome may
trigger disease expression in genetically predisposed individuals. Further studies on
Indian populations may provide clues to how genetics and environment interact to
predispose to UC.
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Table 2  Medical and surgical treatment within 3 mo of diagnosis by ethnic group
White European, n (%) Indian, n (%) Pakistani, n (%) Other, n (%) Total, n (%)
UC
None 5 (4.6) 3 (6.4) 1 (7.7) 2 (9.5) 11 (5.8)
5-ASA 88 (81.5) 42 (89.4) 12 (92.3) 12 (57.1) 154 (81.4)
Steroids 36 (33.3) 16 (34.0) 2 (15.4) 4 (19.0) 58 (30.7)
IM 0 0 0 0 0
Biologics 7 (6.5) 0 0 3 (14.3) 10 (5.2)
Ciclosporin 2 (1.9) 0 0 0 2 (1.0)
Surgery 2 (1.9) 0 0 2 (9.5) 4 (2.1)
CD
None 7 (8.5) 2 (16.7) 0 0 9
5-ASA 31 (37.8) 6 (50.0) 2 (22.2) 2 (28.6) 43
Steroids 34 (41.5) 6 (50.0) 6 (66.7) 4 (57.1) 50
IM 19 (23.2) 2 (16.7) 4 (44.4) 3 (42.9) 28
Biologics 12 (14.6) 0 1 (11.1) 1 (14.3) 14
Other 1 (1.2) 0 0 0 1
Surgery 3 (3.7) 0 0 0 3
IM: Immunomodulators; CD: Crohn’s disease; UC: Ulcerative colitis; 5-ASA: 5-aminosalicylic acid.
Figure 3
Figure 3  Extent of ulcerative colitis at diagnosis across ethnic groups.
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Figure 4
Figure 4  Disease location and behaviour of Crohn’s disease by ethnic group.
ARTICLE HIGHLIGHTS
Research background
Epidemiological studies have described the difference in inflammatory bowel disease (IBD)
epidemiology in ethnic groups.  However,  the studies are predominantly single centre and
retrospective. In the United Kingdom the last IBD incidence study was performed over 20 years
ago.
Research objectives
To describe the incidence and phenotype of IBD in the United Kingdom by ethnic group.
Research methods
A prospective inception cohort study over the course of one year in seven urban centres in the
United Kingdom was performed. Standardised methods across all centres were employed for
case ascertainment. Data was entered real time on the Epicom database.
Research results
Of 339 patients were diagnosed with IBD over the year study period across a population of
2271406 adults. The crude incidence of IBD, ulcerative colitis (UC) and Crohn’s disease for the
total population was 17.0/100000, 11.3/100000 and 5.3/100000 respectively. The age adjusted
incidence of UC in the Indian subgroup was almost three times the White European population
(20.5/100000 and 7.5/100000 respectively).  Indians  were  significantly  more  likely  to  have
extensive disease (41.7% vs 52.7%, P = 0.03)
Research conclusions
The Indian subgroup are particularly at risk of developing UC with a pan-colonic phenotype.
These findings support the hypothesis of an environmental trigger in a genetically susceptible
population. Financial planning and the provision of healthcare services should be reflexive to the
local population and may differ according to the ethnic make-up of the background population.
Research perspectives
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Future studies should incorporate detailed dietary assessment prior to diagnosis to identify
modifiable dietary risk factors. Studying early environmental factors in the paediatric population
may yield clues to disease pathogenesis in the Indian migrant group. A prospective incidence
study in India is required to provide a comparator to the observed trends.
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